Teva CEO: Tough year ahead, but we're hitting cost-cutting targets
The successful Israeli-based generic medication manufacturer has been forced to downsize, but emphasized there will be no second round of restructuring or new site closures.
The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019(photo credit: AMIR COHEN/REUTERS)ByEYTAN HALON
